Background: Alpha-1 antitrypsin deficiency (AATD) is one of the most prevalent inherited diseases in Whites, but identification of affected patients and establishment of the diagnosis is still unsatisfactory. This study assessed the latencies and numbers of physicians involved in identifying AATD patients, and the importance of smoking, vaccination status, and specific augmentation therapy on the course of the disease. Method: Patients from Germany and Austria underwent a single written interview with 28 items. Five hundred and ninety-six patients were addressed and 44.9% replied. Results: The age at symptom onset was 39.1±10.1 years, and the diagnosis was established at the age of 45.1±10.9 years. From the 6-year delay in establishing the diagnosis, 1.4±1.7 (range 0.510.5) years were due to patients' reluctance to seek medical attention. There were 3.2±2.4 (range 113) physicians involved in establishing the diagnosis. Smoking was associated with an earlier onset of respiratory symptoms and lower exercise capacity. Vaccination against pneumococci and/or influenza, and augmentation therapy resulted in significantly fewer exacerbations and fewer emergency room visits. Airway infections and passive smoking during childhood were not found to influence the onset of respiratory symptoms. Conclusions: In conclusion, there is still a large delay between symptom onset and AATD diagnosis. Smoking history, vaccination status, and augmentation therapy have an important impact on the course of the disease.
Introduction
Alpha-1 antitrypsin deficiency (AATD) is one of the most frequent inherited diseases in populations of European descent. In the majority of recognized patients, chronic obstructive pulmonary disease (COPD) is the leading disease manifestation. Early identification of AATD is necessary to initiate appropriate prophylactic and therapeutic measures [Silverman and Sandhaus, 2009 ].
Survey results from the United States have revealed diagnostic delays of many years from the onset of symptoms until the diagnosis AATD was established [Stoller et al. 2005] . Detailed knowledge about the methods and the latencies of identification of AATD patients in Europe is lacking.
Apart from genetic modifiers [Wood et al. 2008] , the course of AATD may be influenced by environmental factors such as smoking [Mannino and Buist, 2007] , increased frequency of childhood airway infections [Dharmage et al. 2009; Johnston et al. 1998 ], exposure to passive smoking in childhood [Svanes et al. 2004] , and others [Teramoto, 2007] . Smokers experience a significantly earlier onset of COPD symptoms, an accelerated progression of the disease [Wu and Eriksson, 1988] , and have a significantly shorter life expectancy compared with nonsmokers [Seersholm and Kok-Jensen, 1995] . Regular vaccinations against influenza and pneumococci have been found to be associated with a more favourable course of the disease [Poole et al. 2006; Christenson et al. 2001 ].
The first objective of this study was to describe the methods of identification of AATD patients, the latencies until establishment of the diagnosis, and the number of physicians involved until the final diagnosis was made. The second aim was to analyse the impact of environmental factors such as smoking, childhood smoke exposure, childhood chest infections, vaccinations, and augmentation therapy on age at symptom onset, exercise capacity, frequencies of exacerbations, hospitalizations, and emergency room visits.
Methods

Study design
This study was designed as a cross-sectional survey of patients with the diagnosis AATD in Germany and Austria.
Protocol
The study consisted of a single written patient interview with a self-administered questionnaire and subsequent analysis of patients' responses.
Inclusion/exclusion criteria
Inclusion criteria were diagnosis of AATD and a minimum age of 18 years. The returned questionnaires were excluded from the analysis if fewer than 20 of the 28 questions were answered, and if one or more responses were contradictory or implausible.
Questionnaire
Patients were interviewed with a 28-item questionnaire, which was developed at Hannover Medical School. All items were in multiple-choice format, except the questions on dates and frequencies. Exercise capacity was assessed by counting the number of flights of stairs that a patient was able to climb without stopping. A flight is defined in this study as 18 stairs. Exacerbations were denoted in everyday language as a 'flare up' of the underlying lung disease. The questions concerning influenza vaccination were related to vaccinations received in the 6 months before the interview.
Distribution of the questionnaires
The questionnaires were mailed to all members of German and Austrian patient organizations (Alpha-1 Deutschland e.V., Alpha-1 Ö sterreich e.V., and Emphysemgruppe Mainz), who together had more than 500 active members at the time of this study. Healthcare systems and the patients' situations are similar in Germany and Austria, providing comparable study conditions. In addition, AATD patients from other interest groups, and from the outpatient clinic of Hannover Medical School were invited to participate. The survey was performed in spring 2008, shortly after the winter period during which COPD symptoms are known to intensify and exacerbations become more frequent.
Definition of index cases and nonindex cases, and subgroup analysis
The 'index case' is the first diagnosed case in a family. Nonindex cases were identified by family screening.
It must be assumed that patient organizations are joined not only by index cases, but also by heterozygous, healthy family members who had been identified by family screening programs. Therefore, the study protocol provided an analysis of the data of all responding participants (complete cohort), as well as an analysis of the subgroup of patients homozygous for the Z variant (subgroup analysis of ZZ patients). The focus on ZZ patients was provided to secure a study cohort with the best achievable genetic homogeneity.
Data management
After the deadline (31 May 2008), the answers of each participant were entered into a database designed at Hannover Medical School. All data were entered and reviewed by independent assistants who were blinded for the outcome parameters of the study.
Statistics
Values are presented as mean±standard deviation (SD) unless otherwise stated. For all answers, the values obtained were compared using a paired t-test, unpaired t-test, the Wilcoxon matched pairs test, or the MannWhitney U-test, as appropriate. For all tests, p < 0.05 was considered significant. The statistics were completed using a standard statistics package (SPSS-software Version 13.0, SPSS Inc., Chicago, IL, USA).
Ethics
The study protocol in its final version was approved by the institutional ethics committee.
Results
Complete cohort
In April 2008, 596 questionnaires were mailed to adult AATD patients in Germany and Austria. By the deadline 6 weeks later, 275 questionnaires had been returned, of which 267 contained complete and plausible information. The return rate was 44.9%.
The distribution of AATD phenotypes is shown in Figure 1 . Patient characteristics of the complete cohort are presented in Table 1 . The vast Therapeutic Advances in Respiratory Disease 4 (5) majority (235 patients; 88%) suffers from pulmonary symptoms only, 15 patients (6%) reported lung and liver disease, and 8 patients (3%) reported liver disease as the only manifestation of AATD. Eighty six patients (32%) were on long-term oxygen treatment, 18 patients (7%) had previously received a double lung transplantation, and 10 patients (4%) were on the waiting list for lung transplantation. One hundred and sixty-one patients (60%) were receiving augmentation therapy (152 weekly, 6 every 14 days, 3 irregularly).
Among all patients with at least one symptom attributable to AATD (COPD, emphysema, bronchial asthma, neonatal jaundice, liver disease in adulthood, panniculits), index cases reported a significantly higher age at symptom onset and a significantly longer latency from the appearance of the first symptom until the first consultation with a physician than nonindex cases. They consulted significantly more physicians before the correct diagnosis was established (Table 2) .
Subgroup analysis of ZZ patients
More detailed analyses were made for a transplant-free, homogeneous subgroup of 166 PiZZ patients with lung disease. This subgroup contained 131 exsmokers, 35 never smokers, and no current smokers. The characteristics from the PiZZ index and nonindex cases are presented in Table 3 .
Age at symptom onset and latencies until the diagnosis was made. Details on the age at symptom onset, age at diagnosis, and number of physicians involved are given in Table 4 . Exsmokers developed their first symptoms at 39.8±8.0 years, versus 43.4±11.4 years in never smokers (p ¼ 0.03). Index cases had significantly longer delays until the diagnosis was established, compared with nonindex cases.
Patients who reported having had exceptional frequent airway infections in childhood (age of 610 years) reported an onset of symptoms at the age of 38.7±8.45 years (n ¼ 24), compared with 40.9±7.9 years in 94 patients who had not suffered frequent airway infections in childhood (p ¼ 0.22). No difference in exercise capacity was seen between respondents who had taken the recommended vaccinations against influenza and/or Therapeutic Advances in Respiratory Disease 4 (5) pneumococci and those who were not vaccinated (p ¼ 0.37).
Frequency of exacerbations. The frequency of exacerbations was assessed for six autumn/ winter months (October 2007 to March 2008 . One quarter of the patients (n ¼ 41) reported that they had no exacerbation. Patients without exacerbation did not differ from those who reported one or more exacerbation(s) in terms of age, the fraction of exsmokers, vaccination status, or augmentation therapy.
In the 125 PiZZ patients with one or more exacerbation(s), the exacerbation frequency was 2.5±1.8 in six autumn/winter months. Exacerbation frequencies were similar in exsmokers compared with never smokers (2.6±1.9 versus 2.1±1.3, respectively; p ¼ 0.14). Exacerbation frequencies differed significantly in patients who had received/had not received vaccinations against pneumococci or influenza or both (2.4±1.8 versus 3.8±1.6, respectively; p ¼ 0.01), and in patients with/without augmentation therapy (2.13±1.24 versus 3.47±2.8, respectively; p ¼ 0.044). Focusing on patients with/without augmentation therapy, there were no significant differences in age, smoking history, or vaccination status.
Hospitalizations. In the complete year 2007, the median hospital stay for ZZ patients was 1 day. Thirty-eight patients had been hospitalized for longer than 1 day, and the average hospital stay in these patients was 17.7±16.9 (range 2 to 90) days. Exsmokers made up 90% of the hospitalized patients. Age, vaccination status, and augmentation therapy had no influence on the frequency or duration of hospitalization.
Emergency room visits. Fifteen patients reported that they had a total of 26 emergency room visits in 2007. Fourteen patients were exsmokers, one was a never smoker. Vaccination against influenza and/or pneumococci had no influence on the frequency of emergency room visits. Six out of 31 patients (19%) without augmentation therapy had 11 emergency room visits, compared with 9 out of 123 patients (7.3%) under augmentation therapy, who together had 15 emergency room visits.
Additional observations. Twenty-two of 166 ZZ patients reported that they had had neonatal jaundice, and two of them (9.1%) developed liver disease in adulthood. Forty-six participants stated that they did not have neonatal jaundice, and three of them (6.5%) have liver disease now. Ninety-eight patients reported that they were unable to give firm information about neonatal jaundice, and six of them (6.1%) reported liver disease in adulthood.
Gender analysis. Analysis of the differences between men and women in terms of age at symptom onset, age at the time of establishment of the diagnosis, smoking status and years smoked, number of physicians consulted, latency of diagnosis, vaccinations, augmentation therapy, frequency of exacerbations, hospitalizations and emergency room visits did not reveal any significant difference.
Discussion
The current study confirms the onset of AATDrelated symptoms at the end of the fourth decade of life. Smoking results in a 4-year earlier onset of symptoms. Patients who developed symptoms attributable to AATD reported a latency of nearly 6 years until the diagnosis was established, of which 1.4 years were due to the reluctance of the patients to seek medical attention. The rates of exacerbations were lower in never smokers and in patients who had received recent immunization against pneumococci or influenza, or who were receiving regular augmentation therapy with human alpha-1 antitrypsin. Augmentation therapy was also associated with fewer emergency room visits.
The delay between symptom onset and the patients' first consultation with the professional medical system was assessed here for the first time. The delay was unexpectedly long, with an average of 1.4±1.7 years (range 0.510 years). This observation supports the previously described low awareness to pulmonary symptoms in the general population [Tsai et al. 2007 ]. After the first presentation, the average number of more than three consulted physicians, and the additional latency of more than 5 years until the diagnosis AATD was established are in line with previous reports from Stoller and colleagues in the United States [Stoller et al. 2005 ] and Koczulla and colleagues in Germany [Koczulla et al. 2008 ]. Both investigators found independently an average total latency from the first symptom until the diagnosis AATD of 5.6 years. Of course, these latencies had been determined in patients who had been identified as cases, while in the vast majority of patients with AATD it is still undetected [Blanco et al. 2006 ].
In the complete cohort, the reported symptom onset in nonindex cases was on average 5 years earlier than in index cases, suggesting a higher alertness to typical symptoms within the families of identified AATD patients. As a consequence, nonindex cases were diagnosed more than 6 years earlier (Table 2) . This is due to a much shorter interval between symptom onset and presentation to the professional medical system, and probably due to a more targeted diagnostic process. In recent years, the recommended family screening programs [American Thoracic Society and European Respiratory Society, 2003] might have been one reason, among others, for the earlier identification of nonindex cases.
In ZZ respondents, first symptoms of AATDrelated lung disease were noted 4 years earlier in the group of exsmokers, compared with never smokers (p ¼ 0.03). Exsmokers were at a more advanced stage of the disease, indicated by the frequency of exacerbations, hospitalizations, emergency room visits, and by the prescription of augmentation therapy. These observations are in agreement with an earlier report in Lancet by Janus and colleagues [Janus et al. 1985] . However, the current and many previous reports must be interpreted with caution, since the proportion of never smokers is relatively small in most epidemiologic studies on AATD.
The subgroup of patients receiving augmentation therapy was on average older and at a more advanced stage of the disease. Among patients who reported having had at least one exacerbation in the previous 6 months, patients receiving augmentation therapy reported a significantly lower exacerbation frequency (p ¼ 0.04). These findings support a previous report by Liebermann, who observed in 143 patients three to five exacerbations per year prior to starting augmentation therapy, which dropped to zero to one exacerbation per year after initiation of regular augmentation therapy [Liebermann, 2000] . Our findings are also in line with the results of EXACTLE (EXAcerbations and CT scans as Lung Endpoints) study, the largest prospective treatment study [Dirksen et al. 2009] , where patients receiving augmentation therapy had a significantly lower severity of exacerbations and less need for emergency room visits compared with patients treated with placebo. These observations might be due to the therapeutic effect of augmentation therapy. On the other hand, patients receiving weekly intravenous augmentation are under very close surveillance by their primary care physician, allowing early intervention for any change in health status. The lower rates of exacerbations and emergency room visits might also be, at least in part, the result of more appropriate care.
The majority of participants in this study had received the recommended vaccinations before the autumn/winter months. The current findings suggest a significantly lower exacerbation frequency in patients vaccinated against pneumococci, influenza or both (p ¼ 0.01). These findings are in contrast to the results of a recent study by Campos and colleagues, who failed to identify a lower exacerbation frequency in 939 AATD participants who had received influenza vaccinations shortly before the 2003 influenza season [Campos et al. 2008 ].
Risk factors from childhood with possible impacts on the development of COPD in adulthood, such as frequent infections of the upper and lower airways [Sveger et al. 1995] and passive smoking [Piitulainen et al. 1998 ] were not found to have significant impact in the current study. Further studies would be justified to assess this question, since the number of participants in the current study who could give firm information about childhood infections or second-hand smoking was small.
The assessment of disease severity in a written survey of AATD patients using the measures 'exercise capacity' and 'rate of exacerbations' is new and unique. Assessing exercise capacity in an interview is difficult and prone to error, but the self-reported measure 'flights of stairs' was previously considered as reliable [Reilly et al. 1999] . In many patients with COPD, the impaired exercise capacity is directly related to their quality of life [Foglio et al. 2007; Dowson et al. 2001 ].
This survey was conducted independently of the established patient registers ('Deutsches/ Ö sterreichisches Register Alpha-1 Antitrypsin-Mangel'), both linked to the Alpha One International Registry (AIR) [Koczulla et al. 2008; Stockley et al. 2007 ]. These registers are updated only once per year, and most items assessed in the current study could not have been answered with the existing registers. The spectrum of this study was broader and different from all previous surveys of patients with AATD [Strange et al. 2006; Stoller et al. 2005; Lieberman, 2000] . Therefore, the development of a new questionnaire was necessary. Since the questionnaire was applied for one single written interview with AATD patients, specific validation was not required.
Limitations of this study
The results in this study depended on the understanding and motivation of the patients to provide details of their disease. Studies employing self-reported patient data are by nature susceptible to attempted deception. Implausible or incomplete information was found in nearly 3% of the questionnaires returned, which were excluded from data analysis to minimize bias in the results.
Most of the data were obtained from members of patient organizations, and it is uncertain whether these respondents are a representative sample of all patients with AATD. It is possible that patients with more advanced disease are more likely to seek support from patients' organizations. However, as long as AATD is a highly underdiagnosed disease with a huge proportion of unrecognized cases, all epidemiologic studies will suffer from some uncertainty.
Owing to the number of participants in this study, further detailed analysis of data, e.g. regression analysis for the characterization of variables modifying the course of the disease, was statistically unfeasible.
In conclusion, AATD-associated respiratory symptoms typically appear at the beginning of the fifth decade of life. In index cases, as well as in nonindex cases, the establishment of the diagnosis is frequently delayed by many years. This is in part due to reservations by patients in seeking medical attention. AATD should be taken into consideration earlier by primary care physicians and by pulmonologists, especially in 'young' patients with COPD. Smoking is a relevant factor for a premature onset of COPD and a more severe course of the disease. The frequency of pulmonary exacerbations may be reduced with vaccinations against influenza and/or pneumococci, and with regular augmentation therapy with human AAT. Childhood airway infections and passive smoking during childhood were not found to have an influence on the onset of respiratory symptoms.
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